FTC Approves Teva Petition to Give Pfizer More Time to Sell Drug
2018年12月19日 - 6:09AM
Dow Jones News
By Patrick Thomas
The Federal Trade Commission said Tuesday that it approved a
petition from Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV)
to reopen a 2012 decision that limited the amount of time Pfizer
Inc. (PFE) can sell the drug Embeda.
In 2012, Watson Pharmaceuticals Inc. and Actavis Inc. merged in
a $5.92 billion deal that made Watson the world's third-largest
maker of generic drugs. The FTC alleged at the time that the merger
might lessen future competition for some generic drugs, including
the abuse-resistant opioid painkiller Embeda.
The commission ordered Watson and Actavis to supply Embeda to
Pfizer Inc. for no longer than four years after Pfizer's relaunch
of Embeda in 2015. The FTC also required Watson and Actavis to
transfer technology for manufacturing Embeda to Pfizer or a third
party. In 2016, Teva acquired Actavis's rights and obligations
under the Embeda supply agreement and continued Watson's plans to
develop a generic version of Embeda.
In its petition, Teva says Pfizer has not completed the tech
transfer of Embeda manufacturing to a third party so Teva can
produce its own version of the generic drug. Due to the four-year
supply limitation, Pfizer can't sell the drug after December,
preventing patients from filling Embeda prescriptions. At Pfizer's
request, Teva said it wants to extend the Embeda supply agreement
for an additional period, allowing patients access to the drug.
Write to Patrick Thomas at patrick.thomas@wsj.com
(END) Dow Jones Newswires
December 18, 2018 15:54 ET (20:54 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 6 2024 まで 7 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 7 2023 まで 7 2024